Denali Wins FDA Approval For AVLAYAH For Hunter Syndrome

The U.S. FDA granted accelerated approval for AVLAYAH, Denali Therapeutics' treatment for Hunter syndrome, marking the first new therapy for the condition in nearly 20 years. AVLAYAH is also the first FDA-approved biologic engineered to cross the blood-brain barrier, a potentially transformative validation for Denali's pipeline and commercial prospects.

Analysis

The U.S. FDA granted accelerated approval for AVLAYAH, Denali Therapeutics' treatment for Hunter syndrome, marking the first new therapy for the condition in nearly 20 years. AVLAYAH is also the first FDA-approved biologic engineered to cross the blood-brain barrier, a potentially transformative validation for Denali's pipeline and commercial prospects.